SynAct Pharma
Synact Pharma: Intends to evaluate AP1189 in Covid19 patients (Redeye)
2020-03-31 10:53
Today Synact announced its intentions to evaluate AP1189 as adjunctive therapy for the prevention of Acute Respiratory Distress Syndrome (ARDS), the most common cause of death among Covid19 patients. Redeye expects a Phase II trial could be initiated within the next months, contingent that financing is secured.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se